In keeping with this finding, apoAI as a component of rHDLs has also been shown to reduce plasma glucose levels in patients with type 2 diabetes, associated with an rHDL-mediated increase in plasma insulin (28). This evidence concerns the gene APOA1 and type 2 diabetes mellitus.